ClinicalTrials.Veeva

Menu

Granuloma Annulare Treated With Rifampin, Ofloxacin, and Minocycline Combination Therapy

Henry Ford Health logo

Henry Ford Health

Status

Completed

Conditions

Granuloma Annulare

Study type

Observational

Funder types

Other

Identifiers

NCT00720980
IRB5074

Details and patient eligibility

About

Granuloma annulare is a benign, usually self-limiting, cutaneous dermatosis, which typically presents as asymptomatic, flesh-colored or red papules, frequently arranged in an annular pattern on the distal extremities. Although localized granuloma annulare is most commonly observed, a generalized or disseminated form can occur. The etiology of granuloma annulare is unknown, however, multiple inciting factors have been proposed. The purpose of the investigators is to review the outcomes of treatment of granuloma annulare (GA) resistant to standard regimens that resolved after a 3-months treatment course of monthly rifampin, ofloxacin, and minocycline (ROM) therapy, successfully used to treat paucibacillary leprosy, a disease with clinical and histopathologic similarity to GA.

Full description

We will document the regimen treatment each patient has had and then review the following from the patient's chart to target our specific aims as outlined above.

  1. What previous treatment options have been or/are currently being used?
  2. How long did the patient take the treatment for?
  3. Was the patient able to discontinue or become less dependent on prior treatment?
  4. Was the disease process slowed by the treatment?;
  5. Were there any side effects that the patient experienced with treatment?

Enrollment

6 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with granuloma annulare who are resistent to the standard treatment.

Exclusion criteria

  • Response to the standard treatment of granuloma annulare.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems